Open AccessCytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction
Author(s) -
Maria Tavakoli-Ardakani,
Shirin Haghighi,
Shervin Shokouhi,
Bahareh AbtahiNaeini,
Mohsen Meidani,
Rezvan Hassanpour,
Ali Saffaei
Publication year - 2019
Publication title -
the eurasian journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.337
H-Index - 13
eISSN - 1308-8742
pISSN - 1308-8734
DOI - 10.5152/eurasianjmed.2019.18459
Subject(s) - medicine , cytarabine , voriconazole , discontinuation , myeloid leukemia , doxorubicin , chemotherapy , pharmacology , regimen , leukemia , oncology , dermatology , antifungal
Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy. The use of cytarabine and doxorubicin in the treatment of acute myeloid leukemia (AML) along with voriconazole can potentially alter the metabolism of the drugs and cause some interactions. In this study, we presented a case of AML who received cytarabine and doxorubicin as a chemotherapy regimen and voriconazole as a prophylactic anti-fungal. In this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration. The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions.